vs
Indivior Pharmaceuticals, Inc.（INDV）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Indivior Pharmaceuticals, Inc.的1.2倍（$411.1M vs $357.0M），UiPath, Inc.净利率更高（48.4% vs 28.9%，领先19.5%），UiPath, Inc.自由现金流更多（$25.1M vs $-245.0M）
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
INDV vs PATH — 直观对比
营收规模更大
PATH
是对方的1.2倍
$357.0M
净利率更高
PATH
高出19.5%
28.9%
自由现金流更多
PATH
多$270.1M
$-245.0M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $357.0M | $411.1M |
| 净利润 | $103.0M | $198.8M |
| 毛利率 | 82.1% | 83.3% |
| 营业利润率 | 22.7% | 3.2% |
| 净利率 | 28.9% | 48.4% |
| 营收同比 | — | 15.9% |
| 净利润同比 | 390.5% | 1966.2% |
| 每股收益（稀释后） | $0.79 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDVPATH
| Q4 25 | $357.0M | $411.1M | ||
| Q3 25 | $314.0M | $361.7M | ||
| Q2 25 | $302.0M | $356.6M | ||
| Q1 25 | $266.0M | $423.6M | ||
| Q4 24 | — | $354.7M | ||
| Q3 24 | $307.0M | $316.3M | ||
| Q2 24 | $299.0M | $335.1M | ||
| Q1 24 | — | $405.3M |
净利润INDVPATH
| Q4 25 | $103.0M | $198.8M | ||
| Q3 25 | $42.0M | $1.6M | ||
| Q2 25 | $18.0M | $-22.6M | ||
| Q1 25 | $47.0M | $51.8M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | $22.0M | $-86.1M | ||
| Q2 24 | $-97.0M | $-28.7M | ||
| Q1 24 | — | $33.9M |
毛利率INDVPATH
| Q4 25 | 82.1% | 83.3% | ||
| Q3 25 | 73.2% | 82.2% | ||
| Q2 25 | 82.8% | 82.1% | ||
| Q1 25 | 83.1% | 84.8% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | 78.5% | 80.0% | ||
| Q2 24 | 73.6% | 83.5% | ||
| Q1 24 | — | 86.8% |
营业利润率INDVPATH
| Q4 25 | 22.7% | 3.2% | ||
| Q3 25 | 13.7% | -5.6% | ||
| Q2 25 | 23.8% | -4.6% | ||
| Q1 25 | 24.8% | 7.9% | ||
| Q4 24 | — | -12.2% | ||
| Q3 24 | 11.4% | -32.7% | ||
| Q2 24 | -39.5% | -14.8% | ||
| Q1 24 | — | 3.7% |
净利率INDVPATH
| Q4 25 | 28.9% | 48.4% | ||
| Q3 25 | 13.4% | 0.4% | ||
| Q2 25 | 6.0% | -6.3% | ||
| Q1 25 | 17.7% | 12.2% | ||
| Q4 24 | — | -3.0% | ||
| Q3 24 | 7.2% | -27.2% | ||
| Q2 24 | -32.4% | -8.6% | ||
| Q1 24 | — | 8.4% |
每股收益（稀释后）INDVPATH
| Q4 25 | $0.79 | $0.37 | ||
| Q3 25 | $0.33 | $0.00 | ||
| Q2 25 | $0.14 | $-0.04 | ||
| Q1 25 | $0.38 | $0.09 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.16 | $-0.15 | ||
| Q2 24 | $-0.72 | $-0.05 | ||
| Q1 24 | — | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.0M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-98.0M | $1.9B |
| 总资产 | $1.2B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INDVPATH
| Q4 25 | $195.0M | $1.4B | ||
| Q3 25 | $445.0M | $1.4B | ||
| Q2 25 | $510.0M | $1.6B | ||
| Q1 25 | $373.0M | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $1.9B |
股东权益INDVPATH
| Q4 25 | $-98.0M | $1.9B | ||
| Q3 25 | $-207.0M | $1.7B | ||
| Q2 25 | $-257.0M | $1.7B | ||
| Q1 25 | $-285.0M | $1.8B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $-310.0M | $1.8B | ||
| Q2 24 | $-281.0M | $2.0B | ||
| Q1 24 | — | $2.0B |
总资产INDVPATH
| Q4 25 | $1.2B | $2.9B | ||
| Q3 25 | $1.4B | $2.6B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.4B | $2.9B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $3.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-221.0M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $-245.0M | $25.1M |
| 自由现金流率自由现金流/营收 | -68.6% | 6.1% |
| 资本支出强度资本支出/营收 | 6.7% | 0.8% |
| 现金转化率经营现金流/净利润 | -2.15× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $-93.0M | — |
8季度趋势，按日历期对齐
经营现金流INDVPATH
| Q4 25 | $-221.0M | $28.3M | ||
| Q3 25 | $-39.0M | $41.6M | ||
| Q2 25 | $158.0M | $119.0M | ||
| Q1 25 | $75.0M | $146.1M | ||
| Q4 24 | — | $28.1M | ||
| Q3 24 | $2.0M | $46.4M | ||
| Q2 24 | $88.0M | $100.0M | ||
| Q1 24 | — | $145.6M |
自由现金流INDVPATH
| Q4 25 | $-245.0M | $25.1M | ||
| Q3 25 | $-59.0M | — | ||
| Q2 25 | $141.0M | $106.2M | ||
| Q1 25 | $70.0M | $138.7M | ||
| Q4 24 | — | $23.2M | ||
| Q3 24 | $-5.0M | $45.0M | ||
| Q2 24 | $84.0M | $98.8M | ||
| Q1 24 | — | $141.8M |
自由现金流率INDVPATH
| Q4 25 | -68.6% | 6.1% | ||
| Q3 25 | -18.8% | — | ||
| Q2 25 | 46.7% | 29.8% | ||
| Q1 25 | 26.3% | 32.7% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | -1.6% | 14.2% | ||
| Q2 24 | 28.1% | 29.5% | ||
| Q1 24 | — | 35.0% |
资本支出强度INDVPATH
| Q4 25 | 6.7% | 0.8% | ||
| Q3 25 | 6.4% | 0.0% | ||
| Q2 25 | 5.6% | 3.6% | ||
| Q1 25 | 1.9% | 1.7% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 2.3% | 0.4% | ||
| Q2 24 | 1.3% | 0.4% | ||
| Q1 24 | — | 0.9% |
现金转化率INDVPATH
| Q4 25 | -2.15× | 0.14× | ||
| Q3 25 | -0.93× | 26.25× | ||
| Q2 25 | 8.78× | — | ||
| Q1 25 | 1.60× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
